Elegen applies innovative technology and methods to produce DNA products that are fundamentally differentiated and disruptive. ENFINIA™ DNA is long linear, NGS-verified DNA that arrives in just 6-8 business days. In comparison to gene fragments from industry-leading suppliers, ENFINIA DNA is >2X longer and >20x more accurate. With industry-leading speed, accuracy, and length, ENFINA DNA can be used directly in most applications without additional assembly or cloning.
Elegen reliably delivers DNA up to 7kb with more than 95% of the molecules sequence perfect. Traditional gene fragments have an error rate of 1 in 3500, meaning laborious traditional cloning is often required for your workflow. Elegen’s unique process yields superior DNA that can often be used without traditional cloning in many high-throughput workflows. When clonal DNA is required, Elegen’s DNA streamlines your workflow by simplifying assembly of longer DNA while letting you pick far fewer colonies.
mRNA vaccine candidates are produced by in vitro transcription, a process where a linearized DNA template with an attached poly-A tail is enzymatically transcribed into an mRNA molecule. To produce enough high-quality DNA template for mRNA synthesis, conventional workflows have relied on a tedious and cumbersome molecular cloning process to produce a master cell bank (MCB). Plasmid DNA is purified from MCB cells, linearized, and transcribed into mRNA using in vitro transcription. ENFINIA DNA is delivered in 6-8 business days already at the length and quality required for in vitro transcription. This eliminates the entire workflow from DNA assembly and cloning to MCB production and plasmid purification, saving up to 15 weeks of time and effort.
The food and agriculture industry relies on metabolic engineering to develop transgenic plants capable of sustainably producing natural products that are challenging to chemically synthesize due to costs or structural complexity. Across cloning cycles, DNA is assembled into large multi-trait cassettes, sometimes >20kb in length, that produce the desired phenotypic behavior. ENFINIA DNA is delivered as long as 7kb and can be assembled directly into a larger construct with minimal or no cloning. This can reduce the time required to build long DNA constructs by 50%.
Despite significant advancements, the field of Synthetic Biology has yet to fully deliver on its promise of a world where we can overcome the challenges we face in human health and our environment by programming biology itself. To help, the team at Elegen is revolutionizing the field by leveraging high-accuracy gene synthesis to produce a new class of DNA. With an industry-leading combination of length, speed, and accuracy, ENFINIA DNA is set to disrupt the gene synthesis status quo and democratize the agile development of biology.
With ENFINIA DNA, customers can now short-circuit the tedious, slow, and costly build phase without compromising on quality. Instead of relying on short DNA that is less than 3kb in length with error rates higher than 1:5000 bp or waiting weeks for clonal synthesis services, get the long DNA you need now without sacrificing quality. Imagine being able to transition designs to functional testing at lightning-fast speeds, receiving DNA at lengths up to 7kb in just 7 days with an average error rate lower than 1:65000 bp. This is the future of Synthetic Biology, and Elegen is leading the charge with a new class of DNA.
|Elegen Standard Complexity||Elegen High Complexity|
|DNA sequence length||300 - 5.500bp||300 - 7,000bp|
|Overall GC content||25 - 65%||25 - 75%|
|100bp GC content||22 - 75%||16 - 80%|
|Local GC variation||up to 60%||up to 60%|
|Repeats||up to 20bp||up to 100bp|
|Homopolymers*||up to 7 bases for G/C and 8 bases for A/T||up to 10 bases for G/C and 20 bases for A/T|
* At this time, the QC methods we use for production do not provide high confidence in fidelity of A/T homopolymer sequences longer than 10bp. A/T homopolymer sequences up to 20bp will be accepted, but we cannot guarantee synthesis quality above 10bp. We are working to address this in the near future.